Advertise
Resources
Member, Beacon International Group, Ltd.
Medicare officials say the federal health insurance program should restrict its coverage of the controversial new Alzheimer’s drug Aduhelm to patients who are participating in approved clinical trials, a move that would limit the number of patients who could use the expensive drug, the New York Times reports. In a preliminary decision released Jan. 11, the Centers for Medicare and Medicaid Services said it had concluded there remain significant doubts about whether the potential benefits of Aduhelm for patients outweigh the safety risks.